The earnings call reflects a strong quarter for PTC Therapeutics, highlighted by the approval and launch of Sephience, which is expected to drive significant future revenue. The company maintains a solid financial position, supporting their strategic initiatives. However, challenges such as the Emflaza market erosion and uncertainty surrounding the vatiquinone NDA remain. Overall, the positive developments, particularly the Sephience launch, outweigh the negatives.

Company Guidance -

Q3 2025

During the PTC Therapeutics Second Quarter 2025 Earnings Conference Call, the company provided key financial metrics and strategic updates, emphasizing the significance of Sephience, recently approved for treating PKU in both the EU and U.S. The company reported total revenue of $179 million for the quarter, with the DMD franchise contributing $96 million. PTC expects Sephience's revenue potential in the U.S. to exceed $1 billion, and it has initiated the European launch in Germany while planning imminent U.S. shipments. The company's cash reserves stand at approximately $1.99 billion, supporting their commercial and R&D initiatives. Additionally, PTC disclosed a strategic transaction of $225 million to purchase annual global net sales payment obligations related to the acquisition of Censa Pharmaceuticals, demonstrating a constructive use of cash reserves. Future expectations include maintaining 25% of European revenue from Translarna despite its conditional marketing authorization nonrenewal, and potential regulatory approvals for Sephience in Japan and Brazil before year-end.

Sephience Approval and Launch

Sephience received EU approval in late June and FDA approval shortly after, with a broad label for PKU patients aged 1 month and above. The U.S. revenue opportunity is expected to exceed $1 billion. European launch began in Germany, with early access mechanisms used in other countries.

Strong Financial Position

PTC closed the quarter with approximately $1.99 billion in cash, supporting all planned commercial and R&D initiatives. This financial strength allows for strategic business development and achieving cash flow breakeven without additional capital.

DMD Franchise Revenue

Achieved $96 million in revenue from the global DMD franchise, including continued Translarna revenue despite nonrenewal of EU conditional license, leveraging Article 117 in Europe.

Evrysdi Royalty Revenue

Roche's second quarter global revenue of approximately $559 million for Evrysdi resulted in $58 million in royalty revenue for PTC.

PTC Therapeutics (PTCT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PTCT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	-1.03 / -	-1.39	―	―	―
Aug 07, 2025	2025 (Q2)	-1.02 / -0.83	-1.29	35.66% (+0.46)	―
May 06, 2025	2025 (Q1)	-1.01 / 10.04	-1.2	936.67% (+11.24)	―
Feb 27, 2025	2024 (Q4)	-0.54 / -0.85	-2.06	58.74% (+1.21)	―
Nov 07, 2024	2024 (Q3)	-1.52 / -1.39	-1.76	21.02% (+0.37)	―
Aug 08, 2024	2024 (Q2)	-1.12 / -1.29	-2.66	51.50% (+1.37)	―
Apr 25, 2024	2024 (Q1)	-1.27 / -1.20	-1.88	36.17% (+0.68)	―
Feb 29, 2024	2023 (Q4)	-0.14 / -2.06	-2.35	12.34% (+0.29)	―
Oct 26, 2023	2023 (Q3)	-1.06 / -1.76	-1.53	-15.03% (-0.23)	―
Aug 03, 2023	2023 (Q2)	-1.62 / -2.66	-2.13	-24.88% (-0.53)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PTCT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$50.36	$45.38	-9.89%
May 06, 2025	$36.19	$40.76	+12.63%
Feb 27, 2025	$50.57	$55.26	+9.27%
Nov 07, 2024	$42.96	$44.28	+3.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PTC Therapeutics (PTCT) report earnings?

PTC Therapeutics (PTCT) is schdueled to report earning on Oct 23, 2025, After Close (Confirmed).

What is PTC Therapeutics (PTCT) earnings time?

PTC Therapeutics (PTCT) earnings time is at Oct 23, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PTCT EPS forecast?

PTCT EPS forecast for the fiscal quarter 2025 (Q3) is -1.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing